<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12872935</article-id><article-id pub-id-type="pmcid-ver">PMC12872935.1</article-id><article-id pub-id-type="pmcaid">12872935</article-id><article-id pub-id-type="pmcaiid">12872935</article-id><article-id pub-id-type="pmid">41660432</article-id><article-id pub-id-type="doi">10.3389/fcimb.2026.1698293</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zheng</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3142161/overview" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Peng</surname><given-names initials="Y">Yang</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3313112/overview" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ou</surname><given-names initials="YX">Yang-xue</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>You</surname><given-names initials="BB">Bi-bo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="Y">Yuan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cheng</surname><given-names initials="M">Mo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xiang</surname><given-names initials="P">Pu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Pharmacy, Dianjiang People’s Hospital of Chongqing</institution>, <city>Chongqing</city>, <country country="cn">China</country></aff><aff id="aff2"><label>2</label><institution>Department of Pharmacy, Chongqing Dianjiang County Hospital of Traditional Chinese Medicine</institution>, <city>Dianjiang</city>, <state>Chongqing</state>, <country country="cn">China</country></aff><author-notes><corresp id="c001"><label>*</label>Correspondence: Mo Cheng, <email xlink:href="mailto:184196499@qq.com" xmlns:xlink="http://www.w3.org/1999/xlink">184196499@qq.com</email>; Pu Xiang, <email xlink:href="mailto:shopnounce@163.com" xmlns:xlink="http://www.w3.org/1999/xlink">shopnounce@163.com</email></corresp><fn fn-type="equal" id="fn003"><label>†</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date date-type="pub" iso-8601-date="2026-01-22" publication-format="electronic"><day>22</day><month>1</month><year>2026</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2026</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">506366</issue-id><elocation-id>1698293</elocation-id><history><date date-type="received"><day>03</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>1</month><year>2026</year></date><date date-type="rev-recd"><day>22</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>06</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-09 15:25:12.677"><day>09</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 Zheng, Peng, Ou, You, Zhang, Cheng, Cheng and Xiang.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Zheng, Peng, Ou, You, Zhang, Cheng, Cheng and Xiang</copyright-holder><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" start_date="2026-01-22" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="fcimb-16-1698293.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><sec><title>Objective</title><p>Ceftazidime/avibactam (CZA), a combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam, was widely used in the treatment of multidrug-resistant (MDR) Gram-negative bacterial pathogens. In light of the growing prevalence of MDR Gram-negative bacterial infection, it is imperative to gain a deeper understanding of the true extent of adverse events (AEs) associated with CZA.</p></sec><sec><title>Methods</title><p>AE reports primarily associated with CZA were retrieved from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2015 to the first quarter of 2025, and all AEs were extracted. AE signal detection was conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) methods. Additionally, a multivariable logistic regression analysis was performed to evaluate the safety of CZA combined with meropenem, explicitly adjusting for confounders such as age, sex, and concomitant nephrotoxins.</p></sec><sec><title>Results</title><p>A total of 2,444 AE reports with CZA as the preferred suspected drug were obtained, identifying 89 preferred terms (PTs) involving 24 system organ classes (SOCs). The ratio of males to females was approximately two times higher in all cases, with the highest number of reports originating from China. Some significant AE signals have been revealed by four methods, including renal and urinary disorders (<italic toggle="yes">n</italic> = 112, ROR 2.49, PRR 2.43, EBGM 2.43, IC 1.28) and hepatobiliary disorders (<italic toggle="yes">n</italic> = 98, ROR 5.04, PRR 4.88, EBGM 4.88, IC 2.29). Regarding combination therapy with meropenem, multivariable analysis revealed a specific safety signal: the risk of respiratory failure remained significantly elevated [adjusted OR (aOR) 3.26, <italic toggle="yes">P</italic> = 0.038] independent of baseline severity. Conversely, acute kidney injury showed no significant association (aOR 1.07, <italic toggle="yes">P</italic> = 0.868), suggesting that the respiratory risk is pharmacodynamically driven rather than a result of generalized clinical deterioration.</p></sec><sec><title>Conclusion</title><p>The present study identified significant and novel AEs signals for CZA. Notably, the specific association between the CZA-meropenem combination and respiratory failure warrants vigilant clinical monitoring, distinct from general disease progression risks.</p></sec></abstract><kwd-group><kwd>adverse events</kwd><kwd>ceftazidime/avibactam</kwd><kwd>combination</kwd><kwd>FAERS</kwd><kwd>respiratory failure</kwd><kwd>safety signals</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="5"/><equation-count count="0"/><ref-count count="31"/><page-count count="13"/><word-count count="6724"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Antibiotic Resistance and New Antimicrobial drugs</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><label>1</label><title>Introduction</title><p>Multidrug-resistant (MDR) Gram-negative bacterial infections, especially those caused by carbapenemase-producing pathogens, including carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Enterobacteriaceae</italic>, not only significantly prolong the length of hospitalization and increase the economic burden of patients but also result in a significantly higher mortality rate, which has become a major challenge for global public health (<xref ref-type="bibr" rid="B21">Torres et al., 2018</xref>; <xref ref-type="bibr" rid="B9">Mills and Marchaim, 2021</xref>; <xref ref-type="bibr" rid="B2">Almangour et al., 2022</xref>). Ceftazidime/avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor combination that effectively enhances the antimicrobial activity of the third-generation, extended-spectrum cephalosporin ceftazidime against multidrug-resistant bacteria (<xref ref-type="bibr" rid="B28">Yahav et al., 2020</xref>). The observed effect can be attributed to the inhibitory effect of avibactam on a broad spectrum of activity, which inhibits Ambler class A, class C, and certain class D β-lactamases (<xref ref-type="bibr" rid="B17">Shields et al., 2017</xref>; <xref ref-type="bibr" rid="B18">Shirley, 2018</xref>). CZA has been approved for marketing in the US, EU, and China since 2015. Subsequent to its emergence as a pivotal pharmaceutical agent, it has been utilized as a primary treatment for complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia, including ventilator-associated pneumonia, and other severe infections caused by MDR Gram-negative bacteria (<xref ref-type="bibr" rid="B3">Carmeli et al., 2016</xref>; <xref ref-type="bibr" rid="B22">van Duin and Bonomo, 2016</xref>; <xref ref-type="bibr" rid="B26">Wagenlehner et al., 2016</xref>). It is currently recommended as a preferred treatment option for carbapenem-resistant Enterobacteriaceae (CRE) and refractory <italic toggle="yes">Pseudomonas aeruginosa</italic> infections by clinical guidelines in multiple nations.</p><p>CZA has been on the market for 10 years, and there has been a paucity of studies conducted on its safety. A more in-depth evaluation of their long-term and comprehensive safety characteristics in the real world is particularly urgent. The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) is one of the world’s largest, most comprehensive, and publicly available databases for post-marketing drug safety monitoring (<xref ref-type="bibr" rid="B15">Sakaeda et al., 2013</xref>). The system functions as a significant data resource for pharmacovigilance research by collecting reports of adverse drug events voluntarily submitted by healthcare professionals, patients, pharmaceutical companies, and regulatory agencies (<xref ref-type="bibr" rid="B10">Morris et al., 2024</xref>). FAERS has become an important tool for the detection of rare or unanticipated adverse drug events due to its broad coverage, large volume of data, and ability to detect potential safety signals at an early stage. In recent years, several studies based on the FAERS database have gradually revealed possible safety issues with a variety of drugs in the real world (<xref ref-type="bibr" rid="B5">Gatti et al., 2021</xref>; <xref ref-type="bibr" rid="B7">Liu et al., 2024</xref>). In 2023, Qi et al. employed the FAERS database to investigate the adverse reactions of CZA, thereby identifying several potential AE signals, including cholestasis, drug-induced liver injury, hepatocellular injury, and hemolytic anemia (<xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>). In addition to the adverse reactions already mentioned in the drug inserts, the use of CZA may be associated with a series of new and potentially serious adverse events (<xref ref-type="bibr" rid="B29">Yao et al., 2024</xref>). However, the investigation did not delve further into the subgroup results, nor did it take into account the impact of drug combinations on AEs for the prevalence of combination regimens centered on CZA in the context of CRE treatment. Therefore, it is imperative to gain a deeper understanding of the true extent of AEs associated with CZA.</p><p>The present study aims to systematically analyze all adverse events reported for CZA since its introduction to the market. The FAERS database will be utilized as a pharmacovigilance tool, and various well-established proportional imbalance analysis methods will be applied. Through the controlled analysis of age and gender subgroups, differences in AE risks among different populations and differences in AEs associated with the most common drug combinations can be assessed, thereby providing a scientific basis for individualized medication.</p></sec><sec id="s2" sec-type="materials|methods"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>Data source and collection</title><p>The data extraction and analysis procedure are shown in <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>. The data were sourced from the FAERS database. This study utilized the raw adverse event report data in ASCII format obtained from the website, covering a total of 41 quarters from the first quarter of 2015 to the first quarter of 2025. The MySQL database management system was used to store, manage, and integrate the database, which contains information such as drug-related adverse events, adverse event reporting dates and outcomes, routes of administration, dosages, cumulative dosages, patient gender and age, and reporting countries. Reported drugs in FAERS are categorized into four groups: Primary Suspect (PS), Secondary Suspect (SS), Concomitant (S), and Interacting (I). Both the brand name and the generic name are employed to identify records related to ceftazidime/avibactam. The search terms include “Avibactam,” “Avycaz,” “Emblaveo,” and “Zavicefta.” In this study, we focused exclusively on data that designated CZA as the ‘prime suspect’. Subsequently, we categorized and characterized AEs in accordance with the preferred terminology (PT) and the system organ classification (SOC) within the International Medical Dictionary for Regulatory Activities (MedDRA 28.0 Edition). This research was carried out and documented in strict adherence to the recommendations outlined in the READUS-PV guidelines. The complete READUS-PV checklist can be accessed in <xref ref-type="supplementary-material" rid="SF1"><bold>Supplementary Table S1</bold></xref>. The data sources are publicly accessible, thus eliminating the need for ethical approval.</p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow chart of data extraction and analysis. A detailed description of the flow chart for data extraction and analysis of adverse events for CZA in the United States Food and Drug Administration Adverse Event Reporting System (FAERS).</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Flowchart of data processing from the FAERS database (2015 Q1 to 2025 Q1). Initial records (16,445,441) filter to exclude duplicates (2,318,872), resulting in 14,126,569 records. Adverse events (AE) for a specific drug are identified (2,444 AEs from 1,082 patients). Data is analyzed using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Outcomes include clinical characteristics, disproportionality analysis, onset time of events, subgroup analysis, and combination analysis.</alt-text></graphic></fig></sec><sec id="s2_2"><label>2.2</label><title>Data processing</title><p>The data was sourced from multiple quarterly database tables, covering various dimensions such as patient information, medication details, adverse event reports, indications, and outcome data (<xref ref-type="bibr" rid="B19">Shu et al., 2022</xref>). The integration of information from disparate database tables into a unified table was achieved by employing SQL queries. The queries employed <italic toggle="yes">INNER JOIN</italic> and <italic toggle="yes">LEFT JOIN</italic> operations to relate data across different tables while retaining all necessary fields. The <italic toggle="yes">INNER JOIN</italic> was used to join the demographic information table with the drug information table. The target drugs were filtered from the drug table. The <italic toggle="yes">LEFT JOIN</italic> integrated the AE information, indication information, and outcome information tables with the main data table to retrieve complete patient records. Invalid or flagged records were removed from the dataset. The records under scrutiny were obtained from deletion tables that were published on a quarterly basis by the FDA. The <italic toggle="yes">UNION</italic> operations were utilized to consolidate deletion tables across multiple quarters into a unified list of records designated for removal. The consolidated list was utilized to eliminate invalid records from the merged primary dataset, thereby generating a refined dataset. The cleaned data table was then validated by checking record counts to ensure the correctness of the cleaning process. The number of records in the cleaned dataset was compared with the expected count. In this study, Python 3.9 was used to execute SQL scripts for data processing tasks.</p></sec><sec id="s2_3"><label>2.3</label><title>Statistical analysis</title><p>Disproportionality analysis was utilized to characterize adverse event reports associated with CZA by comparing them against all other reported drugs within the FAERS database. This analysis typically comprises two components, including frequentist statistics and Bayesian statistics. Frequentist statistics includes the reporting odds ratio (ROR) and proportional reporting ratio (PRR), while Bayesian statistics encompasses the multi-item gamma Poisson shrinker (MGPS) and Bayesian confidence propagation neural network (BCPNN) (<xref ref-type="bibr" rid="B4">Evans et al., 2001</xref>; <xref ref-type="bibr" rid="B24">van Puijenbroek et al., 2002</xref>; <xref ref-type="bibr" rid="B13">Norén et al., 2013</xref>). The algorithm is based on the fourfold table shown in <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>, and the signal mining method and its signal generation conditions are shown in <xref ref-type="table" rid="T2"><bold>Table 2</bold></xref>. In this study, AEs that met the positive thresholds for all four methods (ROR: lower limit of 95% CI &gt; 1, PRR: χ2 S4, lower limit of 95% CI &gt; 1, EBGM: EBGM05 &gt; 2, BCPNN: IC025 &gt; 0) were regarded as potential AE signals of CZA. The integration of the ROR, PRR, MGPS, and BCPNN algorithms is a strategy employed to leverage the strengths inherent in multiple methodologies, thereby mitigating the potential bias that may arise from reliance on a solitary algorithm. To strictly control for potential confounding by indication, a multivariable logistic regression analysis was performed. The ROR was adjusted (aROR) by including covariates such as age, sex, reporting year, and concomitant use of nephrotoxic agents (vancomycin and aminoglycosides) as proxies for disease severity. A p-value &lt; 0.05 was considered statistically significant.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Four grid table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1" valign="middle">Category</th><th align="center" colspan="1" rowspan="1" valign="middle">CZA-related AEs</th><th align="center" colspan="1" rowspan="1" valign="middle">Non-CZA-related AEs</th><th align="center" colspan="1" rowspan="1" valign="middle">Total</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="1" valign="middle">CZA</td><td align="center" colspan="1" rowspan="1" valign="middle">a</td><td align="center" colspan="1" rowspan="1" valign="middle">b</td><td align="center" colspan="1" rowspan="1" valign="middle">a + b</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Other drugs</td><td align="center" colspan="1" rowspan="1" valign="middle">c</td><td align="center" colspan="1" rowspan="1" valign="middle">d</td><td align="center" colspan="1" rowspan="1" valign="middle">c + d</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">Total</td><td align="center" colspan="1" rowspan="1" valign="middle">a + c</td><td align="center" colspan="1" rowspan="1" valign="middle">d + b</td><td align="center" colspan="1" rowspan="1" valign="middle">a + b + c + d</td></tr></tbody></table><table-wrap-foot><fn><p>AEs, adverse events; a, number of reports containing both the target drug and target adverse drug reaction; b, number of reports containing other adverse drug reaction of the target drug; c, number of reports containing the target adverse drug reaction of other drugs; d, number of reports containing other drugs and other adverse drug reactions.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>ROR, PRR, BCPNN, and MGPS methods, formulas, and thresholds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1" valign="middle">Algorithms</th><th align="left" colspan="1" rowspan="1" valign="middle">Equation</th><th align="center" colspan="1" rowspan="1" valign="middle">Criteria</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="2" valign="middle">ROR</td><td align="left" colspan="1" rowspan="1" valign="middle">ROR = ad/b/c</td><td align="center" colspan="1" rowspan="2" valign="middle">lower limit of 95% CI &gt; 1,<break/>N ≥ 3</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">95% CI = e<sup>ln(ROR) ± 1.96(1/a+1/b+1/c+1/d)^0.5</sup></td></tr><tr><td align="center" colspan="1" rowspan="2" valign="middle">PRR</td><td align="left" colspan="1" rowspan="1" valign="middle">PRR = a (c + d)/c/(a+b)</td><td align="center" colspan="1" rowspan="2" valign="middle">PRR ≥ 2, χ2 ≥ 4, N ≥ 3</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">χ<sup>2</sup> = [(ad-bc)^2](a+b + c + d)/[(a + b) (c + d) (a + c) (b + d)]</td></tr><tr><td align="center" colspan="1" rowspan="2" valign="middle">BCPNN</td><td align="left" colspan="1" rowspan="1" valign="middle">IC = log<sub>2</sub>a (a+b + c + d) (a + c) (a + b)</td><td align="center" colspan="1" rowspan="2" valign="middle">IC025 &gt; 0</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">95%CI = E (IC) ± 2V(IC)^0.5</td></tr><tr><td align="center" colspan="1" rowspan="2" valign="middle">MGPS</td><td align="left" colspan="1" rowspan="1" valign="middle">EBGM = a (a+b + c + d)/(a + c)/(a + b)</td><td align="center" colspan="1" rowspan="2" valign="middle">EBGM05 &gt; 2</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">95% CI = e<sup>ln(EBGM) ± 1.96(1/a+1/b+1/c+1/d)^0.5</sup></td></tr></tbody></table><table-wrap-foot><fn><p>a, number of reports containing both the target drug and target adverse drug reaction; b, number of reports containing other adverse drug reaction of the target drug; c, number of reports containing the target adverse drug reaction of other drugs; d, number of reports containing other drugs and other adverse drug reactions. 95% CI, 95% confidence interval; N, the number of reports; χ<sup>2</sup>, chi-squared; IC, information component; IC025, the lower limit of 95% CI of the IC; E (IC), the IC expectations; V (IC), the variance of IC; EBGM, empirical Bayesian geometric mean; EBGM05, the lower limit of 95% CI of EBGM.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3" sec-type="results"><label>3</label><title>Results</title><sec id="s3_1"><label>3.1</label><title>Descriptive characteristics on the AE reports</title><p>A total of 16,445,441 AE reports were registered in the FAERS database from 1 April 2015 to 30 June 2025. These reports involved 1,082 patients and 2,444 AEs, as shown in <xref ref-type="table" rid="T3"><bold>Table 3</bold></xref>. Among all AEs, the proportion of AEs in men (47.4%) was higher than that in women (26.9%). The age distribution showed that 18.9% (204) of elderly patients were over 60 years old, while 15.2% (164) were aged 18–60 years. However, 63.4% (686) of patients had missing ages. The vast majority of the AEs were reported in patients from China (25.9%), followed by the United States (12.0%) and France (9.2%). Most reports (67.9%) were provided by physicians and health professionals.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Clinical characteristic of reports with CZA from the FAERS database (2015 to 2025).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1" valign="middle">Characteristics</th><th align="left" colspan="1" rowspan="1" valign="middle">Case numbers</th><th align="left" colspan="1" rowspan="1" valign="middle">Characteristics</th><th align="left" colspan="1" rowspan="1" valign="middle">Case numbers</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="middle">Number of events</td><td align="left" colspan="1" rowspan="1" valign="middle">1082</td><td align="left" colspan="2" rowspan="1" valign="middle">Reporter</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="middle">Gender</td><td align="left" colspan="1" rowspan="1" valign="middle">Physician</td><td align="left" colspan="1" rowspan="1" valign="middle">538 (49.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Male</td><td align="left" colspan="1" rowspan="1" valign="middle">513 (47.4%)</td><td align="left" colspan="1" rowspan="1" valign="middle">Health professional</td><td align="left" colspan="1" rowspan="1" valign="middle">197 (18.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Female</td><td align="left" colspan="1" rowspan="1" valign="middle">291 (26.9%)</td><td align="left" colspan="1" rowspan="1" valign="middle">Consumer</td><td align="left" colspan="1" rowspan="1" valign="middle">166 (15.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Miss</td><td align="left" colspan="1" rowspan="1" valign="middle">278 (25.7%)</td><td align="left" colspan="1" rowspan="1" valign="middle">Pharmacist</td><td align="left" colspan="1" rowspan="1" valign="middle">143 (13.2%)</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="middle">Age</td><td align="left" colspan="1" rowspan="1" valign="middle">Other health-professional</td><td align="left" colspan="1" rowspan="1" valign="middle">31 (2.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">&lt;18</td><td align="left" colspan="1" rowspan="1" valign="middle">28 (2.6%)</td><td align="left" colspan="1" rowspan="1" valign="middle">Miss</td><td align="left" colspan="1" rowspan="1" valign="middle">7 (0.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">18–60</td><td align="left" colspan="1" rowspan="1" valign="middle">164 (15.2%)</td><td align="left" colspan="2" rowspan="1" valign="middle">Reporting year</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">60–80</td><td align="left" colspan="1" rowspan="1" valign="middle">145 (13.4%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2015</td><td align="left" colspan="1" rowspan="1" valign="middle">13 (1.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">&gt;80</td><td align="left" colspan="1" rowspan="1" valign="middle">59 (5.5%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2016</td><td align="left" colspan="1" rowspan="1" valign="middle">25 (2.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Missing</td><td align="left" colspan="1" rowspan="1" valign="middle">686 (63.4%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2017</td><td align="left" colspan="1" rowspan="1" valign="middle">65 (6.0%)</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="middle">
<bold>Reporting countries (TOP 5)</bold>
</td><td align="left" colspan="1" rowspan="1" valign="middle">2018</td><td align="left" colspan="1" rowspan="1" valign="middle">75 (6.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">China</td><td align="left" colspan="1" rowspan="1" valign="middle">280 (25.9%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2019</td><td align="left" colspan="1" rowspan="1" valign="middle">137 (12.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">United States</td><td align="left" colspan="1" rowspan="1" valign="middle">130 (12.0%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2020</td><td align="left" colspan="1" rowspan="1" valign="middle">117 (10.8%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">France</td><td align="left" colspan="1" rowspan="1" valign="middle">100 (9.2%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2021</td><td align="left" colspan="1" rowspan="1" valign="middle">124 (11.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Italy</td><td align="left" colspan="1" rowspan="1" valign="middle">81 (7.5%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2022</td><td align="left" colspan="1" rowspan="1" valign="middle">120 (11.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Spain</td><td align="left" colspan="1" rowspan="1" valign="middle">57 (5.3%)</td><td align="left" colspan="1" rowspan="1" valign="middle">2023</td><td align="left" colspan="1" rowspan="1" valign="middle">162 (15.0%)</td></tr><tr><td align="left" colspan="2" rowspan="1" valign="middle"/><td align="left" colspan="1" rowspan="1" valign="middle">2024</td><td align="left" colspan="1" rowspan="1" valign="middle">188 (17.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle"/><td align="left" colspan="1" rowspan="1" valign="middle"/><td align="left" colspan="1" rowspan="1" valign="middle">2025</td><td align="left" colspan="1" rowspan="1" valign="middle">56 (5.2%)</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><label>3.2</label><title>Signal AE mining and analysis of AE signals at the PT level</title><p>A total of 24 kinds of SOCs were classified according to MedDRA for the organs and systems involved. Analysis using the ROR, PRR, BCPNN, and EBGM methods identified 87 PT signals, involving 24 SOCs. The signal strengths of the reports associated with CZA at the SOC level are presented in <xref ref-type="table" rid="T4"><bold>Table 4</bold></xref>. The most frequent SOCs were general disorders and administration site conditions (507, 20.7%), injury poisoning, and procedural complications (299, 12.2%), and infections and infestations (290, 11.9%). Important SOCs that met the four criteria were renal and urinary disorders (112, ROR 2.49, PRR 2.43, EBGM 2.43, IC 1.28) and hepatobiliary disorders (98, ROR 5.04, PRR 4.88, EBGM 4.88, IC 2.29). Furthermore, the top 30 AEs were identified, ranked by the number of AE reports, and 23 AEs with significant safety signals were found using four algorithms at the PT level (<xref ref-type="table" rid="T5"><bold>Table 5</bold></xref>). In our study, the highest number of CZA AEs was death, followed by pathogen resistance, septic shock, decreased platelet count, renal failure, and acute kidney injury. It is important to note that our data mining revealed several important AEs not explicitly mentioned in the specifications for CZA, including multiple organ dysfunction syndrome, respiratory failure, hypotension, and others. Our analysis identified additional AEs that contribute to an enhanced comprehension of the safety profile of CZA.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>The signal strength of AEs of CZA at the SOC level in FAERS database.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1" valign="middle">System organ class (SOC)</th><th align="center" colspan="1" rowspan="1" valign="middle">Case</th><th align="center" colspan="1" rowspan="1" valign="middle">ROR (95%)</th><th align="center" colspan="1" rowspan="1" valign="middle">PRR(χ2)</th><th align="center" colspan="1" rowspan="1" valign="middle">EBGM(EBGM05)</th><th align="center" colspan="1" rowspan="1" valign="middle">IC(IC025)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="middle">General disorders and administration site conditions</td><td align="center" colspan="1" rowspan="1" valign="middle">507 (20.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.20(1.09–1.32)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.16 (13.54)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.16(1.05)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.21(0.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Injury, poisoning and procedural complications</td><td align="center" colspan="1" rowspan="1" valign="middle">299 (12.2%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.03(0.92–1.17)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.03 (0.28)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.03(0.91)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.04(−0.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Infections and infestations</td><td align="center" colspan="1" rowspan="1" valign="middle">290 (11.9%)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.35(2.08–2.66)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.19 (197.94)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.19(1.94)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.13(0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Investigations</td><td align="center" colspan="1" rowspan="1" valign="middle">276 (11.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.08(1.84–2.36)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.96 (137.47)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.96(1.73)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.97(0.8)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Nervous system disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">208 (8.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.10(0.95–1.27)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.09 (1.72)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.09(0.95)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.13(−0.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Skin and subcutaneous tissue disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">124 (5.1%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.89(0.74–1.06)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.89 (1.65)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.89(0.75)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.16(−0.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Renal and urinary disorders*</td><td align="center" colspan="1" rowspan="1" valign="middle">112 (4.6%)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.49(2.06–3.01)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.43 (95.64)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.43(2.01)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.28(1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Gastrointestinal disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">102 (4.2%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.48(0.40–0.59)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.50 (54.34)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.50(0.41)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.99(−1.3)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Hepatobiliary disorders*</td><td align="center" colspan="1" rowspan="1" valign="middle">98 (4.0%)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.04(4.12–6.17)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.88 (304.82)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.88(3.99)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.29(1.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Blood and lymphatic system disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">79 (3.2%)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.02(1.61–2.52)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.98 (39.24)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.98(1.59)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.99(0.6)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Respiratory, thoracic and mediastinal disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">77 (3.2%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.68(0.54–0.85)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.69 (11.50)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.69(0.55)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.54(−0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Psychiatric disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">65 (2.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.49(0.38–0.63)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.50 (33.66)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.50(0.39)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.99(−1.3)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Cardiac disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">45 (1.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.86(0.64–1.16)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.86 (0.97)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.86(0.64)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.21(−0.6)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Metabolism and nutrition disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">35 (1.4%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.70(0.50–0.97)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.70 (4.54)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.70(0.50)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.51(−1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Vascular disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">32 (1.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.68(0.48–0.96)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.68 (4.89)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.68(0.48)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.56(−1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Neoplasms benign, malignant and unspecified</td><td align="center" colspan="1" rowspan="1" valign="middle">19 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.26(0.17–0.41)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.27 (38.79)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.27(0.17)</td><td align="center" colspan="1" rowspan="1" valign="middle">−1.89(−2.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Immune system disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">17 (0.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.58(0.36–0.94)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.59 (5.03)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.59(0.36)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.77(−1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Musculoskeletal and connective tissue disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">17 (0.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.13(0.08–0.21)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.14 (97.69)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.14(0.08)</td><td align="center" colspan="1" rowspan="1" valign="middle">−2.87(−3.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Eye disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">14 (0.6%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.29(0.17–0.48)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.29 (24.77)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.29(0.17)</td><td align="center" colspan="1" rowspan="1" valign="middle">−1.78(−2.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Surgical and medical procedures</td><td align="center" colspan="1" rowspan="1" valign="middle">7 (0.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.20(0.09–0.41)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.20 (23.05)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.20(0.09)</td><td align="center" colspan="1" rowspan="1" valign="middle">−2.34(−3.2)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Ear and labyrinth disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">7 (0.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.66(0.31–1.38)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.66 (1.25)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.66(0.31)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.60(−1.6)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Product issues</td><td align="center" colspan="1" rowspan="1" valign="middle">7 (0.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.15(0.07–0.32)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.16 (32.28)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.16(0.07)</td><td align="center" colspan="1" rowspan="1" valign="middle">−2.67(−3.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Congenital, familial and genetic disorders</td><td align="center" colspan="1" rowspan="1" valign="middle">5 (0.2%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.78(0.33–1.88)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.78 (0.30)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.78(0.33)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.35(−1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Pregnancy, puerperium and perinatal conditions</td><td align="center" colspan="1" rowspan="1" valign="middle">2 (0.1%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.21(0.05–0.86)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.22 (5.74)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.22(0.05)</td><td align="center" colspan="1" rowspan="1" valign="middle">−2.22(−3.4)</td></tr></tbody></table><table-wrap-foot><fn><p>Asterisks (*) indicate statistically significant signals in four algorithms; ROR, reporting odds ratio; PRR, proportional reporting ratio; EBGM, empirical Bayesian geometric mean; EBGM05, the lower limit of the 95% CI of EBGM; IC, information component; IC025, the lower limit of the 95% CI of the IC; CI, confidence interval; AEs, adverse events.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><p>The signal strength of adverse events of CZA at the PTs level in FAERS database.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1" valign="middle">PT</th><th align="center" colspan="1" rowspan="1" valign="middle">Case</th><th align="center" colspan="1" rowspan="1" valign="middle">ROR (95% Cl)</th><th align="center" colspan="1" rowspan="1" valign="middle">PRR(χ2)</th><th align="center" colspan="1" rowspan="1" valign="middle">EBGM (EBGM05)</th><th align="center" colspan="1" rowspan="1" valign="middle">IC(IC025)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="middle">Death*</td><td align="center" colspan="1" rowspan="1" valign="middle">163 (6.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.10(4.35–5.98)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.83(501.12)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.82(4.12)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.27(2.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Pathogen resistance*</td><td align="center" colspan="1" rowspan="1" valign="middle">105 (4.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">61.64(50.67–74.97)</td><td align="center" colspan="1" rowspan="1" valign="middle">59.03(5973.41)</td><td align="center" colspan="1" rowspan="1" valign="middle">58.83(48.59)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.88(5.61)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Septic shock*</td><td align="center" colspan="1" rowspan="1" valign="middle">32 (1.3%)</td><td align="center" colspan="1" rowspan="1" valign="middle">19.34(13.64–27.42)</td><td align="center" colspan="1" rowspan="1" valign="middle">19.10(548.84)</td><td align="center" colspan="1" rowspan="1" valign="middle">19.09(13.46)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.25(3.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Platelet count decreased*</td><td align="center" colspan="1" rowspan="1" valign="middle">28 (1.1%)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.69(4.61–9.71)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.62(133.85)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.62(4.56)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.73(1.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Renal failure*</td><td align="center" colspan="1" rowspan="1" valign="middle">27 (1.1%)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.98(3.41–7.28)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.94(84.97)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.94(3.38)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.30(1.6)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Pyrexia</td><td align="center" colspan="1" rowspan="1" valign="middle">27 (1.1%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.98(1.35–2.89)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.97(12.90)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.97(1.35)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.98(0.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Acute kidney injury*</td><td align="center" colspan="1" rowspan="1" valign="middle">27 (1.1%)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.64(3.17–6.78)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.60(76.22)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.60(3.15)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.20(1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Blood creatinine increased*</td><td align="center" colspan="1" rowspan="1" valign="middle">25 (1.0%)</td><td align="center" colspan="1" rowspan="1" valign="middle">9.60(6.48–14.24)</td><td align="center" colspan="1" rowspan="1" valign="middle">9.52(190.65)</td><td align="center" colspan="1" rowspan="1" valign="middle">9.51(6.41)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.25(2.3)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Multiple organ dysfunction syndrome*</td><td align="center" colspan="1" rowspan="1" valign="middle">24 (1.0%)</td><td align="center" colspan="1" rowspan="1" valign="middle">24.07(16.10–35.98)</td><td align="center" colspan="1" rowspan="1" valign="middle">23.84(524.84)</td><td align="center" colspan="1" rowspan="1" valign="middle">23.82(15.93)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.57(3.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Renal impairment*</td><td align="center" colspan="1" rowspan="1" valign="middle">22 (0.9%)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.80(4.47–10.35)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.75(107.92)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.75(4.44)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.75(1.8)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Diarrhea</td><td align="center" colspan="1" rowspan="1" valign="middle">21 (0.9%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.84(0.55–1.29)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.84(0.65)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.84(0.55)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.25(−0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Encephalopathy*</td><td align="center" colspan="1" rowspan="1" valign="middle">20 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">21.03(13.54–32.66)</td><td align="center" colspan="1" rowspan="1" valign="middle">20.86(378.03)</td><td align="center" colspan="1" rowspan="1" valign="middle">20.85(13.42)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.38(2.8)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Respiratory failure*</td><td align="center" colspan="1" rowspan="1" valign="middle">19 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.56(4.18–10.30)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.51(88.77)</td><td align="center" colspan="1" rowspan="1" valign="middle">6.51(4.15)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.70(1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Seizure*</td><td align="center" colspan="1" rowspan="1" valign="middle">19 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.38(2.79–6.88)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.36(49.19)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.35(2.77)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.12(1.3)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Pneumonia</td><td align="center" colspan="1" rowspan="1" valign="middle">19 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.51(0.96–2.37)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.50(3.21)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.50(0.96)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.59(−0.1)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Rash</td><td align="center" colspan="1" rowspan="1" valign="middle">19 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.14(0.72–1.79)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.14(0.32)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.14(0.72)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.19(−0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Hepatic function abnormal*</td><td align="center" colspan="1" rowspan="1" valign="middle">19 (0.8%)</td><td align="center" colspan="1" rowspan="1" valign="middle">13.38(8.52–21.02)</td><td align="center" colspan="1" rowspan="1" valign="middle">13.29(215.87)</td><td align="center" colspan="1" rowspan="1" valign="middle">13.28(8.45)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.73(2.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Sepsis*</td><td align="center" colspan="1" rowspan="1" valign="middle">17 (0.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.86(2.40–6.22)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.84(35.80)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.84(2.38)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.94(1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Erythema</td><td align="center" colspan="1" rowspan="1" valign="middle">16 (0.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.98(1.21–3.23)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.97(7.67)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.97(1.20)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.98(0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Thrombocytopenia*</td><td align="center" colspan="1" rowspan="1" valign="middle">16 (0.7%)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.68(2.25–6.01)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.66(30.98)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.66(2.24)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.87(1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Cholestasis*</td><td align="center" colspan="1" rowspan="1" valign="middle">15 (0.6%)</td><td align="center" colspan="1" rowspan="1" valign="middle">20.16(12.13–33.50)</td><td align="center" colspan="1" rowspan="1" valign="middle">20.04(271.27)</td><td align="center" colspan="1" rowspan="1" valign="middle">20.03(12.05)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.32(2.5)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Hepatic enzyme increased*</td><td align="center" colspan="1" rowspan="1" valign="middle">15 (0.6%)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.88(3.54–9.77)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.85(60.39)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.85(3.52)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.55(1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Drug-induced liver injury*</td><td align="center" colspan="1" rowspan="1" valign="middle">15 (0.6%)</td><td align="center" colspan="1" rowspan="1" valign="middle">13.76(8.28–22.87)</td><td align="center" colspan="1" rowspan="1" valign="middle">13.68(176.31)</td><td align="center" colspan="1" rowspan="1" valign="middle">13.68(8.23)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.77(2.2)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Delirium*</td><td align="center" colspan="1" rowspan="1" valign="middle">14 (0.6%)</td><td align="center" colspan="1" rowspan="1" valign="middle">10.47(6.19–17.71)</td><td align="center" colspan="1" rowspan="1" valign="middle">10.42(119.17)</td><td align="center" colspan="1" rowspan="1" valign="middle">10.41(6.16)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.38(1.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">White blood cell count decreased</td><td align="center" colspan="1" rowspan="1" valign="middle">13 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.02(1.75–5.22)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.01(17.52)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.01(1.75)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.59(0.6)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Blood bilirubin increased*</td><td align="center" colspan="1" rowspan="1" valign="middle">13 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">11.98(6.94–20.66)</td><td align="center" colspan="1" rowspan="1" valign="middle">11.92(130.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">11.91(6.91)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.57(2.0)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Pruritus</td><td align="center" colspan="1" rowspan="1" valign="middle">13 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.92(0.53–1.59)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.92(0.09)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.92(0.53)</td><td align="center" colspan="1" rowspan="1" valign="middle">−0.12(−0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Neurotoxicity*</td><td align="center" colspan="1" rowspan="1" valign="middle">12 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">18.47(10.47–32.58)</td><td align="center" colspan="1" rowspan="1" valign="middle">18.38(197.16)</td><td align="center" colspan="1" rowspan="1" valign="middle">18.37(10.42)</td><td align="center" colspan="1" rowspan="1" valign="middle">4.20(2.2)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Depressed level of consciousness*</td><td align="center" colspan="1" rowspan="1" valign="middle">11 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">7.07(3.91–12.78)</td><td align="center" colspan="1" rowspan="1" valign="middle">7.04(57.04)</td><td align="center" colspan="1" rowspan="1" valign="middle">7.04(3.89)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.82(1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Hypotension</td><td align="center" colspan="1" rowspan="1" valign="middle">11 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.39(0.77–2.51)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.39(1.19)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.39(0.77)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.47(−0.4)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Coma*</td><td align="center" colspan="1" rowspan="1" valign="middle">11 (0.5%)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.84(3.23–10.55)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.81(43.87)</td><td align="center" colspan="1" rowspan="1" valign="middle">5.81(3.21)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.54(1.2)</td></tr></tbody></table><table-wrap-foot><fn><p>Asterisks (*) indicate statistically significant signals in four algorithms; PT, preferred term; ROR, reporting odds ratio; PRR, proportional reporting ratio; EBGM, empirical Bayesian geometric mean; EBGM05, the lower limit of the 95% CI of EBGM; IC, information component; IC025, the lower limit of the 95% CI of the IC; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_3"><label>3.3</label><title>Time to onset of CZA-associated AEs</title><p>Based on the time period of AE, we observed that from 2015 to 2020, the risk of CZA-induced nausea and elevated serum creatinine events remained relatively low. However, after 2020, there was a significant increase in the risks of pathogen resistance, treatment failure, drug ineffectiveness, death, and hypernatremia. Of all reported AEs, 400 contained complete and accurate detailed information on the timing of the occurrence. The median time to AE onset was 5.1 days (IQR 1–10 days), and it can be seen that most AEs (223, 55.8%) occurred within the first 5 days of CZA use as shown in <xref ref-type="fig" rid="f2"><bold>Figures 2</bold></xref> and <xref ref-type="fig" rid="f3"><bold>3</bold></xref>. In the assessment of Weibull 3-parameter analysis (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>), the shape parameter β and its upper limit of 95% CI were found to be less than 1, indicating a decreasing probability of AEs over time. It is noteworthy that a small minority of 4.8% of AEs occurred 30 days after the commencement of CZA treatment. These findings underscore the significance of monitoring patients for potential AEs during the initial 10 days of CZA treatment and throughout the entire treatment process.</p><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Volcano plot related to AEs from 2015 to 2019 and 2020 to 2025.</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Volcano plot comparing risk ratios and p-values from 2015-2019 versus 2020-2025. Points are color-coded: purple for higher risk in 2015-2019, green for higher risk in 2020-2025, and gray for not significant. Key labels include “Pathogen Resistance”, “Treatment Failure”, and “Drug Ineffective” on the right, and “Blood Creatinine Increased” and “Diarrhoea” on the left.</alt-text></graphic></fig><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Time to onset of CZA-related AEs.</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Bar chart showing time to event onset in days with six categories: 0-5 days, 6-10 days, 11-20 days, 21-30 days, 31-60 days, and over 60 days. The chart displays percentages on the left and counts on the right. Most events occurred in 0-5 days (55.8%, 223), followed by 6-10 days (19.5%, 78), 11-20 days (14.0%, 56), 21-30 days (6.0%, 24), 31-60 days (4.0%, 16), and over 60 days (0.8%, 3).</alt-text></graphic></fig><fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Time to onset analysis of AEs after treatment with CZA.</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g004.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Graph illustrating a Weibull distribution fit for time to event, showing a density curve over time in days. Key statistics include a median of 5.1, interquartile range of 1.0 to 10.0, and a minimum-maximum range of 1 to 366 days. Parameters α equals 7.97 with a 95 percent confidence interval of 6.91 to 9.08, and β equals 0.83 with a 95 percent confidence interval of 0.75 to 0.97. The failure type is categorized as early.</alt-text></graphic></fig></sec><sec id="s3_4"><label>3.4</label><title>Safety of CZA according to age and gender</title><p>Subgroup analyses were conducted to mitigate the influence of confounding factors related to demographic characteristics. The PT that had the highest number of reported cases was death and hypernatremia in the 18- to 64-year-old and &gt;64-year-old subgroups, respectively. However, there were no significant differences between gender subgroups, with death being the most common AE. The results for the various subgroups are displayed in a volcano plot, where events are negatively correlated on the left side of the x-axis, indicating a lower incidence of PT in that subgroup, and positively correlated on the right side of the x-axis, denoting a higher incidence of PT in that subgroup, as shown in <xref ref-type="fig" rid="f5"><bold>Figures 5</bold></xref> and <xref ref-type="fig" rid="f6"><bold>6</bold></xref>. In the age subgroup, the risk of hypotension, delirium, and death was found to be lower after the administration of CZA to subjects aged between 18 and 64 years. In the gender-based subgroup analysis, the female population exhibited an elevated risk of mortality, acute kidney injury, renal failure, sepsis, and epilepsy. This information is critical for clinical management and can guide clinical decision makers in developing personalized treatment plans based on subgroup characteristics.</p><fig id="f5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Age subgroup analysis.</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g005.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Volcano plot comparing risks in groups aged sixty-five and older versus eighteen to sixty-four. The x-axis represents the log two transformed ROR ratio and the y-axis shows negative log ten of the p-value. Key points include hypotension, delirium, and death, all with p-values less than 0.05, presented on the left side, indicating higher risk in the younger age group. The legend highlights risks higher in each group and non-significant results are marked gray.</alt-text></graphic></fig><fig id="f6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Gender subgroup analysis.</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g006.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Volcano plot comparing female and male risks. The x-axis shows log base two of the ROR ratio (female/male), and the y-axis shows negative log of p-value. Purple dots indicate higher risk in females for conditions like death, acute kidney injury, sepsis, renal injury, and epilepsy. Gray dots are not significant. Legend indicates color coding for risk significance.</alt-text></graphic></fig></sec><sec id="s3_5"><label>3.5</label><title>Safety of CZA versus CZA in combination with meropenem</title><p>CZA is recommended for use alone in KPC enzyme-producing CRE and in combination with other drugs in metallo-β-lactamase–producing CRE infections and mixed infections. Therefore, we analyzed the use of combination therapy further to investigate whether the AEs identified were due to drug interactions. Based on the frequency of combination use and the categories suspected, the primary drugs used in combination were meropenem, tigecycline, aztreonam, and vancomycin. We found that when CZA was used alone, the risks of neurological disorders, injury, poisoning, and procedural complications were lower. However, when CZA was combined with meropenem, the risks of general disorders and administration site conditions, infections and infestations, gastrointestinal disorders, and respiratory, thoracic, and mediastinal disorders were higher, as shown in <xref ref-type="fig" rid="f7"><bold>Figure 7</bold></xref>.</p><fig id="f7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Disproportionately reported SOC for CZA versus CZA and meropenem in the FAERS database. The forest plot shows ROR with 95% confidence intervals.</p></caption><graphic orientation="portrait" position="float" xlink:href="fcimb-16-1698293-g007.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Forest plot showing the reporting odds ratio (ROR) and 95% confidence intervals for various system organ classes. Each disorder is color-coded and plotted against the ROR axis. Notable RORs include respiratory, thoracic and mediastinal disorders at 2.18, and congenital, familial and genetic disorders at 1.87. Some disorders show RORs below one, indicating reduced reporting frequency.</alt-text></graphic></fig><p>In the multivariable logistic regression analysis (<xref ref-type="supplementary-material" rid="SF2"><bold>Supplementary Table S2</bold></xref>), the risk of respiratory failure remained significantly elevated in the combination group (aOR 3.26, 95% CI [1.07–9.93], <italic toggle="yes">P</italic> = 0.038), supporting a pharmacodynamic interaction. Crucially, no significant association was observed for acute kidney injury (AKI) (aOR 1.07, <italic toggle="yes">P</italic> = 0.868). This dissociation suggests that the respiratory signal is a specific drug effect rather than a proxy for generalized clinical deterioration. Conversely, the persistent signals for death and septic shock likely reflect residual confounding by indication, driven by the critical baseline status of patients requiring salvage therapy.</p></sec></sec><sec id="s4" sec-type="discussion"><label>4</label><title>Discussion</title><p>CZA offers important treatment options for MDR Gram-negative bacterial infections. The scarcity of preclinical data makes it crucial to collect pharmacovigilance data from post-marketing systems where AEs are reported, which could greatly improve drug quality standards. This study explored the risk status of its AEs from the perspective of signaling risk by accessing CZA data from the FAERS database and performing signal mining.</p><p>We observed that AE reports have shown an overall upward trend from 2015 to 2025, with the number of recently recorded AEs continuing to increase, which may reflect the efficacy of CZA in the treatment of infections caused by drug-resistant bacteria. The study results highlight the importance of continuous monitoring of AEs. We compared the clinical characteristics of patients treated with CZA. The incidence of AEs was significantly higher in male patients (47.4%) than in female patients (26.9%). Middle-aged and young adults were the primary reporting population, accounting for the majority of cases (18–60 years: 15.2%), while the elderly population aged 80 years and above was relatively small, primarily due to the absence of age data in most cases (63.4%).</p><sec id="s4_1"><label>4.1</label><title>Basic information</title><p>Our consistency analysis indicates that CZA was associated with significant AEs in 24 SOC categories, including general disorders and administration site reactions, injuries, poisoning, and surgical complications; infections and infestations; investigations; nervous system disorders; and skin and subcutaneous tissue disorders. Specifically, CZA is commonly associated with death, pathogen resistance, thrombocytopenia, and renal failure, as well as elevated serum creatinine, diarrhea, encephalopathy, and respiratory failure. It is worth noting that Zhang et al. explicitly pointed out that pathogen resistance is the strongest AE signal in CZA therapy (<xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>). Data from Phase II/III clinical trials showed that the most common AEs were positive direct antiglobulin tests, nausea, and diarrhea (<xref ref-type="bibr" rid="B18">Shirley, 2018</xref>). Overall, as the clinical application population expands and the duration of use increases, the AE profile of CZA shows a trend toward increased severity, shifting from primarily gastrointestinal adverse reactions in the early stages to life-threatening outcomes such as nephrotoxicity, neurotoxicity, and resistance.</p></sec><sec id="s4_2"><label>4.2</label><title>Significant AEs detected by four methods</title><p>Based on the analysis results, we found that the following AEs were significant in all four detection methods and occurred more than 20 times, including death, pathogen resistance, septic shock, decreased platelet count, renal failure, acute kidney injury, increased blood creatinine, multiple organ dysfunction syndrome, renal impairment, and encephalopathy. It broadly covers renal and urinary system diseases, blood and lymphatic system disorders, nervous system diseases, and infections and infestations.</p><p>Interpretation of treatment failure and disease progression signals. Although death and septic shock reached the threshold for signal detection, these findings likely mirror the underlying clinical status of the patients. As CZA is frequently reserved for salvage therapy in high-risk infections, these reports often represent disease severity or treatment failure rather than a direct pharmacological reaction. Acknowledging this protopathic bias is essential for a balanced safety assessment and prevents the misattribution of illness-related complications to the drug’s inherent toxicity.</p><p>The mechanism between CZA and hematological and lymphatic system disorders, particularly thrombocytopenia, primarily involves three aspects. Of paramount importance is the effect of bone marrow suppression. Ceftazidime has been demonstrated to directly inhibit the proliferation and differentiation of bone marrow megakaryocytes, thereby reducing platelet production (<xref ref-type="bibr" rid="B12">Nie et al., 2021</xref>). This dose-dependent effect is closely related to drug accumulation caused by renal insufficiency. Second, ceftazidime would bind to platelet membrane protein and interact with platelet antigen (<xref ref-type="bibr" rid="B8">Loo et al., 2012</xref>; <xref ref-type="bibr" rid="B1">Ali et al., 2020</xref>). These antibodies then form antibody-drug conjugates, which activate the complement system or macrophage phagocytosis, accelerating platelet destruction. Furthermore, although avibactam does not possess any intrinsic capacity for direct bone marrow suppression, it does inhibit renal tubular organic anion transporters (OAT1/3), thereby delaying ceftazidime excretion and increasing its exposure concentration in bone marrow and blood (<xref ref-type="bibr" rid="B25">Vishwanathan et al., 2014</xref>). This, in turn, results in an indirect enhancement of its toxicity to platelets. Hematological and lymphatic system disorders typically occur 5–14 days following administration, presenting as mild to moderate thrombocytopenia, which may resolve within one to two weeks of discontinuation. Nevertheless, for high-risk populations, such as those with renal impairment or concurrent use of other nephrotoxic medications, closer monitoring of blood counts is necessary.</p><p>The occurrence of renal dysfunction and urinary tract disorders, including acute kidney injury and elevated creatinine levels in patients treated with CZA, is primarily attributable to the direct tubular toxicity of the ceftazidime component, crystal deposition, and immune-mediated injury (<xref ref-type="bibr" rid="B16">Shi et al., 2024</xref>). Ceftazidime has been observed to accumulate in renal tubular epithelial cells, resulting in the inhibition of mitochondrial complex I activity, the induction of oxidative stress, and the formation of crystals in acidic urine (<xref ref-type="bibr" rid="B16">Shi et al., 2024</xref>). This phenomenon is attributed to the significant decrease in the solubility of ceftazidime at urine pH values below 5.5, consequently leading to tubular cell necrosis and obstruction. Furthermore, ceftazidime, as a hapten, has been demonstrated to induce acute interstitial nephritis, characterized by lymphocytic infiltration and eosinophilic urine. The risk factors for renal dysfunction and urinary tract disorders include oliguria, high-dose administration, renal insufficiency, and concomitant use of nephrotoxic drugs. Therefore, strict dose adjustment, forced hydration, and monitoring of creatinine levels are prerequisites for its clinical application.</p><p>For nervous system diseases, ceftazidime has been observed to penetrate the blood-brain barrier, thereby competitively inhibiting the binding of the central inhibitory neurotransmitter gamma-aminobutyric acid (GABA) to its receptors (<xref ref-type="bibr" rid="B14">Pingue et al., 2020</xref>; <xref ref-type="bibr" rid="B23">Vanneste et al., 2024</xref>). This results in abnormal increases in neuronal excitability, manifesting in symptoms such as delirium, myoclonus, and seizures. In patients diagnosed with meningitis, the cerebrospinal fluid/serum concentration ratio of CZA reaches 0.35–0.59, indicating its capacity to effectively penetrate the blood–brain barrier in inflammatory states (<xref ref-type="bibr" rid="B27">Xu et al., 2024</xref>). This characteristic confers therapeutic advantages in the treatment of central nervous system infections but also increases the risk of neurotoxicity.</p></sec><sec id="s4_3"><label>4.3</label><title>Analysis of subgroup results</title><p>From the subgroup results, younger patients who received CZA had lower risks of hypotension, delirium, and death. This may be attributed to the younger population having fewer comorbidities, stronger drug metabolism capabilities, and better immune function, thereby reducing the risk of serious adverse events, such as delirium caused by drug accumulation-induced neurotoxicity. However, the investigation revealed no clear high-risk events in elderly patients. It was hypothesized that this was due to the absence of age data in more than 60% of the reports, resulting in the identification of no statistically significant AE. In the gender subgroup, males who received CZA had a higher risk of death, acute kidney injury, sepsis, and epilepsy. The higher risk in males may stem from the interplay of multiple factors. For instance, differences in pharmacokinetics/pharmacodynamics, such as higher average body weight and greater muscle mass in males, may lead to variations in drug distribution volume and clearance, thereby affecting effective drug exposure or increasing renal burden (<xref ref-type="bibr" rid="B11">Nicolson et al., 2010</xref>). The prevalence and severity of underlying conditions may be higher in male patient populations, and unhealthy lifestyle habits are more common, factors that are themselves associated with increased risks of adverse outcomes. Additionally, existing evidence suggests that gender influences immune responses, and males may have distinct regulatory mechanisms for inflammatory responses to certain infections, potentially impacting the onset and progression of sepsis (<xref ref-type="bibr" rid="B6">Klein and Flanagan, 2016</xref>). Therefore, it is recommended that blood counts, renal function, and neurological symptoms be closely monitored in male and elderly patients during treatment with CZA.</p></sec><sec id="s4_4"><label>4.4</label><title>Analysis of CZA versus CZA in combination with meropenem</title><p>Descriptive analysis indicated elevated reporting rates for respiratory disorders in patients receiving CZA combined with meropenem. While signals for death and septic shock likely reflect confounding by indication (i.e., higher baseline severity in patients with metallo-ive analysis indicate CRE), the risk of respiratory failure remained distinctly elevated (aOR 3.26) after multivariable adjustment.</p><p>Crucially, the lack of a comparable signal for acute kidney injury (aOR 1.07) argues against the hypothesis that respiratory failure is merely a secondary consequence of renal toxicity (<xref ref-type="bibr" rid="B20">Steffens et al., 2021</xref>). Instead, this dissociation suggests a specific pharmacodynamic interaction, likely involving synergistic neuromuscular blockade. Meropenem is known to antagonize GABA receptors, increasing neuronal excitability, while ceftazidime can inhibit presynaptic acetylcholine release by chelating calcium ions at the neuromuscular junction (<xref ref-type="bibr" rid="B30">Zhanel et al., 2009</xref>). Concomitant use may potentiate this blockade, leading to respiratory muscle weakness, particularly in patients with drug accumulation.</p><p>Additionally, immune-mediated mechanisms cannot be excluded. As ceftazidime acts as a hapten and meropenem can induce histamine release, the combination could theoretically amplify the risk of acute immune-mediated pneumonitis and alveolar edema. Collectively, these findings highlight a specific safety signal that warrants vigilant monitoring of respiratory status during combination therapy.</p></sec></sec><sec id="s5"><label>5</label><title>Limitations</title><p>Our study has several limitations, primarily stemming from the inherent nature of the FAERS database as a spontaneous reporting system. First, the data are influenced by reporting biases, including under-reporting, duplicate records, and systematic distortions like the Weber effect and notoriety bias, potentially compromising information completeness and accuracy. Second, reports frequently lack granular clinical details has several laboratory values, imaging findings, and comprehensive medical histories verily limiting the depth of clinical assessment. Third, the analysis is susceptible to “confounding by indication,” where adverse events arising from the underlying pathology (e.g., complications of severe infection) may be indistinguishable from drug-induced toxicity. Additionally, while we performed multivariable logistic regression to adjust for age, sex, and concomitant nephrotoxins, other potential confounders — such as specific comorbidities and granular disease severity scores (e.g., APACHE II)—could not be fully captured due to database limitations. Finally, since the total number of patients exposed to CZA remains unknown (denominator lacking), absolute incidence rates of adverse events cannot be determined. Consequently, the identified signals represent statistical associations rather than established biological causality, particularly given the absence of rigorous adjudication for individual reports using standard tools like the Naranjo Scale. Therefore, prospective cohort studies or clinical trials are essential for further validation.</p></sec><sec id="s6" sec-type="conclusions"><label>6</label><title>Conclusion</title><p>This study employed pharmacovigilance analysis to assess the potential AEs of CZA using the FAERS database. The most commonly reported AEs include death, pathogen resistance, septic shock, decreased platelet count, renal failure, pyrexia, and acute kidney injury, emphasizing the need for monitoring and management during its use. Particularly, some newly identified AEs, including multiple organ dysfunction syndrome, respiratory failure, and hypotension, should be carefully consideration. The post-marketing safety information for CZA contributes to minimizing the risks associated with its use.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge the data provided by FAERS database.</p></ack><fn-group><fn fn-type="edited-by" id="n1"><p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3256589" xmlns:xlink="http://www.w3.org/1999/xlink">Gong Yanqiao</ext-link>, Minda Hospital of Hubei Minzu University, China</p></fn><fn fn-type="reviewed-by" id="n2"><p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1872364" xmlns:xlink="http://www.w3.org/1999/xlink">Dongxuan Li</ext-link>, Third Affiliated Hospital of Chongqing Medical University, China</p><p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3263232" xmlns:xlink="http://www.w3.org/1999/xlink">Adrian Bekier</ext-link>, Medical University of Lodz, Poland</p></fn></fn-group><sec id="s7" sec-type="data-availability"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <uri xlink:href="https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</uri>.</p></sec><sec id="s8" sec-type="author-contributions"><title>Author contributions</title><p>XZ: Visualization, Investigation, Writing – review &amp; editing, Writing – original draft, Validation, Resources, Data curation, Funding acquisition, Formal Analysis, Supervision, Conceptualization, Methodology, Software, Project administration. YP: Writing – review &amp; editing, Data curation, Writing – original draft. Y-XO: Data curation, Methodology, Writing – review &amp; editing, Writing – original draft. B-BY: Data curation, Writing – review &amp; editing. LZ: Data curation, Writing – review &amp; editing. YC: Writing – review &amp; editing, Data curation. MC: Funding acquisition, Writing – review &amp; editing, Investigation. PX: Writing – review &amp; editing, Funding acquisition, Supervision, Data curation.</p></sec><sec id="s10" sec-type="COI-statement"><title>Conflict of interest</title><p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec id="s11" sec-type="ai-statement"><title>Generative AI statement</title><p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec id="s12" sec-type="disclaimer"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s13" sec-type="supplementary-material"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2026.1698293/full#supplementary-material" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.frontiersin.org/articles/10.3389/fcimb.2026.1698293/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SF1" orientation="portrait" position="float"><label>Supplementary Table 1</label><caption><p>The READUS-PV checklist.</p></caption><media orientation="portrait" position="float" xlink:href="Table1.docx" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="SF2" orientation="portrait" position="float"><label>Supplementary Table 2</label><caption><p>Multivariable logistic regression analysis of clinical outcomes associated with CZA combination therapy compared to monotherapy.</p></caption><media orientation="portrait" position="float" xlink:href="Table2.docx" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ali</surname><given-names>M. S.</given-names></name>
<name name-style="western"><surname>Berencsi</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Marinier</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Deltour</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Perez-Guthann</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Pedersen</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2020</year>). 
<article-title>et al: Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance</article-title>. <source>Osteoporos Int.</source>
<volume>31</volume>, <fpage>2425</fpage>–<lpage>2438</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00198-020-05580-0</pub-id>, PMID: 
<pub-id pub-id-type="pmid">32757044</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Almangour</surname><given-names>T. A.</given-names></name>
<name name-style="western"><surname>Ghonem</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Aljabri</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Alruwaili</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Al Musawa</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Damfu</surname><given-names>N.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title>et al: Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study</article-title>. <source>Infect. Drug Resist.</source>
<volume>15</volume>, <fpage>211</fpage>–<lpage>221</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S349004</pub-id>, PMID: 
<pub-id pub-id-type="pmid">35125877</pub-id>
<pub-id pub-id-type="pmcid">PMC8807865</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Carmeli</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Armstrong</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Laud</surname><given-names>P. J.</given-names></name>
<name name-style="western"><surname>Newell</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Stone</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Wardman</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2016</year>). 
<article-title>Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study</article-title>. <source>Lancet Infect. Dis.</source>
<volume>16</volume>, <fpage>661</fpage>–<lpage>673</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(16)30004-4</pub-id>, PMID: 
<pub-id pub-id-type="pmid">27107460</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Evans</surname><given-names>S. J.</given-names></name>
<name name-style="western"><surname>Waller</surname><given-names>P. C.</given-names></name>
<name name-style="western"><surname>Davis</surname><given-names>S.</given-names></name>
</person-group> (<year>2001</year>). 
<article-title>Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports</article-title>. <source>Pharmacoepidemiol. Drug Saf.</source>
<volume>10</volume>, <fpage>483</fpage>–<lpage>486</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pds.677</pub-id>, PMID: 
<pub-id pub-id-type="pmid">11828828</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gatti</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Raschi</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>De Ponti</surname><given-names>F.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source>
<volume>40</volume>, <fpage>1169</fpage>–<lpage>1176</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10096-020-04149-3</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33415492</pub-id>
<pub-id pub-id-type="pmcid">PMC8139903</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Klein</surname><given-names>S. L.</given-names></name>
<name name-style="western"><surname>Flanagan</surname><given-names>K. L.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Sex differences in immune responses</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>16</volume>, <fpage>626</fpage>–<lpage>638</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id>, PMID: 
<pub-id pub-id-type="pmid">27546235</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>W.-H.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>H.-M.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C.-H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>A.-X.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database</article-title>. <source>J. Headache Pain</source>
<volume>25</volume>, <fpage>206</fpage>. doi: 0.1186/s10194-024-01913-0, PMID: 
<pub-id pub-id-type="pmid">39587512</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s10194-024-01913-0</pub-id><pub-id pub-id-type="pmcid">PMC11587596</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Loo</surname><given-names>A. S.</given-names></name>
<name name-style="western"><surname>Gerzenshtein</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ison</surname><given-names>M. G.</given-names></name>
</person-group> (<year>2012</year>). 
<article-title>Antimicrobial drug-induced thrombocytopenia: a review of the literature</article-title>. <source>Semin. Thromb. Hemost.</source>
<volume>38</volume>, <fpage>818</fpage>–<lpage>829</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0032-1328882</pub-id>, PMID: 
<pub-id pub-id-type="pmid">23081819</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mills</surname><given-names>J. P.</given-names></name>
<name name-style="western"><surname>Marchaim</surname><given-names>D.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Multidrug-resistant gram-negative bacteria: infection prevention and control update</article-title>. <source>Infect. Dis. Clin. North Am.</source>
<volume>35</volume>, <fpage>969</fpage>–<lpage>994</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.idc.2021.08.001</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34752228</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Morris</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Ali</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Drug repurposing using FDA adverse event reporting system (FAERS) database</article-title>. <source>Curr. Drug Targets</source>
<volume>25</volume>, <fpage>454</fpage>–<lpage>464</lpage>. doi: <pub-id pub-id-type="doi">10.2174/0113894501290296240327081624</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38566381</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Nicolson</surname><given-names>T. J.</given-names></name>
<name name-style="western"><surname>Mellor</surname><given-names>H. R.</given-names></name>
<name name-style="western"><surname>Roberts</surname><given-names>R. R. A.</given-names></name>
</person-group> (<year>2010</year>). 
<article-title>Gender differences in drug toxicity</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>31</volume>, <fpage>108</fpage>–<lpage>114</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tips.2009.12.001</pub-id>, PMID: 
<pub-id pub-id-type="pmid">20117848</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Nie</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Jia</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>et al: detection of drug-induced thrombocytopenia signals in children using routine electronic medical records</article-title>. <source>Front. Pharmacol.</source>
<volume>12</volume>, <elocation-id>756207</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2021.756207</pub-id>, PMID: 
<pub-id pub-id-type="pmid">34867372</pub-id>
<pub-id pub-id-type="pmcid">PMC8633439</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Norén</surname><given-names>G. N.</given-names></name>
<name name-style="western"><surname>Hopstadius</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bate</surname><given-names>A.</given-names></name>
</person-group> (<year>2013</year>). 
<article-title>Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery</article-title>. <source>Stat. Methods Med. Res.</source>
<volume>22</volume>, <fpage>57</fpage>–<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0962280211403604</pub-id>, PMID: 
<pub-id pub-id-type="pmid">21705438</pub-id>
<pub-id pub-id-type="pmcid">PMC6331976</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pingue</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Penati</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Nardone</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Franciotta</surname><given-names>D.</given-names></name>
</person-group> (<year>2020</year>). 
<article-title>Ceftazidime/avibactam neurotoxicity in an adult patient with normal renal function</article-title>. <source>Clin. Microbiol. Infect</source>. <volume>27</volume>, <fpage>795</fpage>–<lpage>796</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2020.11.031</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33285278</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sakaeda</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tamon</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kadoyama</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Okuno</surname><given-names>Y.</given-names></name>
</person-group> (<year>2013</year>). 
<article-title>Data mining of the public version of the FDA Adverse Event Reporting System</article-title>. <source>Int. J. Med. Sci.</source>
<volume>10</volume>, <fpage>796</fpage>–<lpage>803</lpage>. doi: <pub-id pub-id-type="doi">10.7150/ijms.6048</pub-id>, PMID: 
<pub-id pub-id-type="pmid">23794943</pub-id>
<pub-id pub-id-type="pmcid">PMC3689877</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Mi</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Ceftazidime-avibactam induced renal disorders: past and present</article-title>. <source>Front. Pharmacol.</source>
<volume>15</volume>, <elocation-id>1329307</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2024.1329307</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38318141</pub-id>
<pub-id pub-id-type="pmcid">PMC10838962</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shields</surname><given-names>R. K.</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>M. H.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Press</surname><given-names>E. G.</given-names></name>
<name name-style="western"><surname>Potoski</surname><given-names>B. A.</given-names></name>
<name name-style="western"><surname>Marini</surname><given-names>R. V.</given-names></name>
<etal/>
</person-group>. (<year>2017</year>). 
<article-title>Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>61</volume>, <elocation-id>e00883-17</elocation-id>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00883-17</pub-id>, PMID: 
<pub-id pub-id-type="pmid">28559250</pub-id>
<pub-id pub-id-type="pmcid">PMC5527595</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shirley</surname><given-names>M.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>Ceftazidime-avibactam: A review in the treatment of serious gram-negative bacterial infections</article-title>. <source>Drugs</source>
<volume>78</volume>, <fpage>675</fpage>–<lpage>692</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40265-018-0902-x</pub-id>, PMID: 
<pub-id pub-id-type="pmid">29671219</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system</article-title>. <source>Front. Public Health</source>
<volume>10</volume>, <elocation-id>996179</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fpubh.2022.996179</pub-id>, PMID: 
<pub-id pub-id-type="pmid">36339230</pub-id>
<pub-id pub-id-type="pmcid">PMC9631444</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Steffens</surname><given-names>N. A.</given-names></name>
<name name-style="western"><surname>Zimmermann</surname><given-names>E. S.</given-names></name>
<name name-style="western"><surname>Nichelle</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Brucker</surname><given-names>N.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Meropenem use and therapeutic drug monitoring in clinical practice: a literature review</article-title>. <source>J. Clin. Pharm. Ther.</source>
<volume>46</volume>, <fpage>610</fpage>–<lpage>621</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcpt.13369</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33533509</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Torres</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Zhong</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Pachl</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Timsit</surname><given-names>J.-F.</given-names></name>
<name name-style="western"><surname>Kollef</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). 
<article-title>et al: Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial</article-title>. <source>Lancet Infect. Dis.</source>
<volume>18</volume>, <fpage>285</fpage>–<lpage>295</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30747-8</pub-id>, PMID: 
<pub-id pub-id-type="pmid">29254862</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>van Duin</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Bonomo</surname><given-names>R. A.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations</article-title>. <source>Clin. Infect. Dis.</source>
<volume>63</volume>, <fpage>234</fpage>–<lpage>241</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciw243</pub-id>, PMID: 
<pub-id pub-id-type="pmid">27098166</pub-id>
<pub-id pub-id-type="pmcid">PMC4928383</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vanneste</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Gijsen</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Maertens</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Van Paesschen</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Debaveye</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wauters</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review</article-title>. <source>Infection</source>
<volume>52</volume>, <fpage>1113</fpage>–<lpage>1123</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-023-02167-9</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38305827</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>van Puijenbroek</surname><given-names>E. P.</given-names></name>
<name name-style="western"><surname>Bate</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Leufkens</surname><given-names>H. G. M.</given-names></name>
<name name-style="western"><surname>Lindquist</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Orre</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Egberts</surname><given-names>A. C. G.</given-names></name>
</person-group> (<year>2002</year>). 
<article-title>A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions</article-title>. <source>Pharmacoepidemiol. Drug Saf.</source>
<volume>11</volume>, <fpage>3</fpage>–<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pds.668</pub-id>, PMID: 
<pub-id pub-id-type="pmid">11998548</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vishwanathan</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Mair</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Atherton</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Clarkson-Jones</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Edeki</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2014</year>). 
<article-title>Assessment of the mass balance recovery and metabolite profile of avibactam in humans and <italic toggle="yes">in vitro</italic> drug-drug interaction potential</article-title>. <source>Drug Metab. Dispos.</source>
<volume>42</volume>, <fpage>932</fpage>–<lpage>942</lpage>. doi: <pub-id pub-id-type="doi">10.1124/dmd.113.055335</pub-id>, PMID: 
<pub-id pub-id-type="pmid">24616266</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wagenlehner</surname><given-names>F. M.</given-names></name>
<name name-style="western"><surname>Sobel</surname><given-names>J. D.</given-names></name>
<name name-style="western"><surname>Newell</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Armstrong</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Stone</surname><given-names>G. G.</given-names></name>
<etal/>
</person-group>. (<year>2016</year>). 
<article-title>Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program</article-title>. <source>Clin. Infect. Dis.</source>
<volume>63</volume>, <fpage>754</fpage>–<lpage>762</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciw378</pub-id>, PMID: 
<pub-id pub-id-type="pmid">27313268</pub-id>
<pub-id pub-id-type="pmcid">PMC4996135</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yuan</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>79</volume>, <fpage>820</fpage>–<lpage>825</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkae035</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38366379</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yahav</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Giske</surname><given-names>C. G.</given-names></name>
<name name-style="western"><surname>Grāmatniece</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Abodakpi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Tam</surname><given-names>V. H.</given-names></name>
<name name-style="western"><surname>Leibovici</surname><given-names>L.</given-names></name>
</person-group> (<year>2020</year>). 
<article-title>New β-lactam-β-lactamase inhibitor combinations</article-title>. <source>Clin. Microbiol. Rev.</source>
<volume>34</volume>, <elocation-id>e00115-20</elocation-id>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00115-20</pub-id>, PMID: 
<pub-id pub-id-type="pmid">33177185</pub-id>
<pub-id pub-id-type="pmcid">PMC7667665</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Gan</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>A real-world pharmacovigilance study of ceftazidime/avibactam: data mining of the food and drug administration adverse event reporting system database</article-title>. <source>J. Clin. Pharmacol.</source>
<volume>64</volume>, <fpage>820</fpage>–<lpage>827</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.2420</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38375685</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhanel</surname><given-names>G. G.</given-names></name>
<name name-style="western"><surname>Ketter</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Rubinstein</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Friedland</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Redman</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>). 
<article-title>Overview of seizure-inducing potential of doripenem</article-title>. <source>Drug Saf.</source>
<volume>32</volume>, <fpage>709</fpage>–<lpage>716</lpage>. doi: <pub-id pub-id-type="doi">10.2165/00002018-200932090-00001</pub-id>, PMID: 
<pub-id pub-id-type="pmid">19670912</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Qiao</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Safety evaluation of ceftazidime/avibactam based on FAERS database</article-title>. <source>Infection</source>
<volume>52</volume>, <fpage>2195</fpage>–<lpage>2205</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-024-02248-3</pub-id>, PMID: 
<pub-id pub-id-type="pmid">38842750</pub-id>
</mixed-citation></ref></ref-list></back></article>